Astermark J - Search Results

1

Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.

Astermark J, Altisent C, Batorova A, Diniz MJ, Gringeri A, Holme PA, Karafoulidou A, Lopez-Fernández MF, Reipert BM, Rocino A, Schiavoni M, von Depka M, Windyga J, Fijnvandraat K; European Haemophilia Therapy Standardisation Board. Astermark J, et al. Haemophilia. 2010 Sep 1;16(5):747-66. doi: 10.1111/j.1365-2516.2010.02231.x. Epub 2010 Apr 14. Haemophilia. 2010. PMID: 20398077 Review.

2

The Malmö-Klaipeda WFH twinning programme: a comparative description of the haemophilia cohorts.

Berntorp E, Astermark J, Jurgutis R, Lethagen S, Petersson C. Berntorp E, et al. Among authors: astermark j. Haemophilia. 1998 Mar;4(2):79-82. doi: 10.1046/j.1365-2516.1998.00169.x. Haemophilia. 1998. PMID: 9873842 Clinical Trial.

3

The Malmö model for immune tolerance induction: impact of previous treatment on outcome.

Carlborg E, Astermark J, Lethagen S, Ljung R, Berntorp E. Carlborg E, et al. Among authors: astermark j. Haemophilia. 2000 Nov;6(6):639-42. doi: 10.1046/j.1365-2516.2000.00436.x. Haemophilia. 2000. PMID: 11122389

4

The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients.

Astermark J, Berntorp E, White GC, Kroner BL; MIBS Study Group. Astermark J, et al. Haemophilia. 2001 May;7(3):267-72. doi: 10.1046/j.1365-2516.2001.00510.x. Haemophilia. 2001. PMID: 11380630

5

Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors.

Astermark J, Ekman M, Berntorp E. Astermark J, et al. Br J Haematol. 2002 Nov;119(2):342-7. doi: 10.1046/j.1365-2141.2002.03853.x. Br J Haematol. 2002. PMID: 12406066 Free article.

6

Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.

Fischer K, Astermark J, van der Bom JG, Ljung R, Berntorp E, Grobbee DE, van den Berg HM. Fischer K, et al. Among authors: astermark j. Haemophilia. 2002 Nov;8(6):753-60. doi: 10.1046/j.1365-2516.2002.00694.x. Haemophilia. 2002. PMID: 12410643

7

Unresolved issues in prophylaxis.

Brown SA, Aledort LM, Astermark J, Berntorp E, van den Berg M, Blanchette V, Donfield S, Gringeri A, Hilgartner M, Kulkarni R, Leissinger C, Negrier C, Nuss R, Petterson H, Petrini P, Poulios N, Schramm W; Round Table Group. Brown SA, et al. Among authors: astermark j. Haemophilia. 2002 Nov;8(6):817-21. doi: 10.1046/j.1365-2516.2002.00685.x. Haemophilia. 2002. PMID: 12410654 No abstract available.

8

Consensus perspectives on prophylactic therapy for haemophilia: summary statement.

Berntorp E, Astermark J, Björkman S, Blanchette VS, Fischer K, Giangrande PL, Gringeri A, Ljung RC, Manco-Johnson MJ, Morfini M, Kilcoyne RF, Petrini P, Rodriguez-Merchan EC, Schramm W, Shapiro A, van den Berg HM, Hart C. Berntorp E, et al. Among authors: astermark j. Haemophilia. 2003 May;9 Suppl 1:1-4. doi: 10.1046/j.1365-2516.9.s1.17.x. Haemophilia. 2003. PMID: 12709030

9

When to start and when to stop primary prophylaxis in patients with severe haemophilia.

Astermark J. Astermark J. Haemophilia. 2003 May;9 Suppl 1:32-6; discussion 37. doi: 10.1046/j.1365-2516.9.s1.1.x. Haemophilia. 2003. PMID: 12709035 Review.

10

Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.

Astermark J, Voorberg J, Lenk H, DiMichele D, Shapiro A, Tjönnfjord G, Berntorp E. Astermark J, et al. Haemophilia. 2003 Sep;9(5):567-72. doi: 10.1046/j.1365-2516.2003.00802.x. Haemophilia. 2003. PMID: 14511295

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

179 results

Search Page